Alzheimer's Disease Drug Landscape 2026
Disease-modifying therapies, symptomatic treatments, and clinical trial intelligence
Overview
Alzheimer's disease is the most common cause of dementia, affecting nearly 7 million Americans and projected to reach 13 million by 2050. After two decades of clinical failures, the approval of anti-amyloid antibodies lecanemab (2023) and donanemab (2024) proved that clearing amyloid plaques can slow cognitive decline - but the effect is modest (25-35% slowing), limited to early-stage patients with confirmed amyloid, and comes with significant practical barriers: IV infusions, amyloid PET or CSF confirmation, regular MRI monitoring for ARIA (brain swelling/bleeding in 20-35% of patients), and annual costs exceeding $26,000. Real-world uptake has been slow. Traditional symptomatic treatments (cholinesterase inhibitors, memantine) remain widely used but do not alter disease progression.
The pipeline is active with anti-tau antibodies, neuroinflammation modulators (TREM2, CD33), synaptic protection agents, and GLP-1 agonists repurposed for neuroprotection. Blood-based biomarkers like p-tau217 may solve the access bottleneck faster than any new drug. Major investments from Eli Lilly, Biogen, Eisai, Roche, Novo Nordisk, and numerous biotechs make Alzheimer's one of the most competitive therapeutic areas in drug development.
Historical Context
First described in 1906 by German psychiatrist Alois Alzheimer, who examined a 51-year-old woman named Auguste Deter with progressive memory loss, confusion, and behavioral changes. Upon her death in 1906, Alzheimer performed an autopsy and identified the hallmark plaques and tangles in her brain tissue using a silver staining technique. His colleague Emil Kraepelin coined the term 'Alzheimer's disease' in 1910. For decades it was considered a rare presenile dementia until the 1970s when researchers recognized it was the same pathology seen in elderly dementia patients.
Treatment Evolution
Symptomatic treatments
Disease-modifying therapies
Year = first FDA approval for alzheimer's disease. Dashed = still in clinical development.
Symptomatic treatments (gray) manage the cognitive and behavioral symptoms of Alzheimer's - memory loss, confusion, agitation - but do not alter the underlying disease. Cholinesterase inhibitors (Aricept, Exelon, Razadyne) boost acetylcholine, a neurotransmitter depleted as neurons die. NMDA antagonists (Namenda) regulate glutamate signaling to reduce excitotoxicity. Both provide modest, temporary benefit. The disease continues to progress.
Disease-modifying therapies (blue) target the biological mechanisms driving neurodegeneration itself - amyloid plaques, tau tangles, neuroinflammation. The goal is to slow or halt disease progression, not just manage symptoms. After a 20-year gap with no new mechanism class approved, anti-amyloid antibodies broke through in 2023. Multiple new approaches (anti-tau, GLP-1, TREM2) are now in clinical testing.
Mechanism Landscape
Current alzheimer's disease treatments span 3 distinct mechanism classes: Anti-amyloid (2), Cholinesterase Inhibitor (2), NMDA Receptor Antagonist (1). Anti-amyloid leads with 2 approved drugs.
FDA-Approved Drugs
5 originators + 0 biosimilars5 approved therapies for alzheimer's disease across 3 mechanism classes: Anti-amyloid (2), Cholinesterase Inhibitor (2), NMDA Receptor Antagonist (1).
| Drug | Company | Mechanism | Alzheimer's Disease Approval |
|---|---|---|---|
| KISUNLA DONANEMAB-AZBT | Eli Lilly | Anti-amyloid | 2024 |
| LEQEMBI LECANEMAB-IRMB | EISAI | Anti-amyloid | 2023 |
| NAMENDA MEMANTINE HYDROCHLORIDE | AbbVie | NMDA Receptor Antagonist | 2003 |
| RAZADYNE GALANTAMINE HYDROBROMIDE | Johnson & Johnson | Cholinesterase Inhibitor | 2001 |
| EXELON RIVASTIGMINE TARTRATE | Novartis | Cholinesterase Inhibitor | 2000 |
0 biosimilars shown inline. Purple = biosimilar of the originator above.
Pivotal Trial Data
Phase 3 efficacy results for disease-modifying therapies. Both trials measure cognitive decline over 18 months, but use different scales: CDR-SB (Clinical Dementia Rating - Sum of Boxes) tracks memory, orientation, judgment, and daily function; iADRS (Integrated Alzheimer's Disease Rating Scale) combines cognition and daily living into a single score. A "27% slowing" means patients on the drug declined 27% less than patients on placebo - not that the disease was 27% cured. These are modest but statistically significant effects in early-stage patients with confirmed amyloid pathology.
Leqembi
lecanemab - Eisai / Biogen
CLARITY AD - 1,795 patients, 18 months
Safety
ARIA-E (brain edema): 12.6% vs 1.7% placebo
ARIA-H (microhemorrhage): 17.3% vs 9% placebo
Kisunla
donanemab - Eli Lilly
TRAILBLAZER-ALZ 2 - 1,736 patients, 76 weeks
Safety
ARIA-E (brain edema): 24% vs 2.1% placebo
ARIA-H (microhemorrhage): 31.4% vs 13.6% placebo
Pipeline Snapshot
Active clinical trials for alzheimer's disease drugs across all development phases.
Key Companies
Major pharmaceutical companies active in alzheimer's disease drug development.
Showing top companies by approved drug count and pipeline activity.
Explore Further
Emerging class: Amyloid beta
2 Phase 3 programs targeting Amyloid beta in alzheimer's disease. No approved drugs in this class yet - first pivotal readouts could reshape the treatment landscape.
Emerging drugs at unvalidated targets
See all emerging drugs →No current Phase 3 candidates in alzheimer's disease target an unvalidated molecule — the pipeline here is dominated by next-generation versions of validated mechanism classes. See emerging drugs in other therapeutic areas →
Active Phase 3 Trials
10 active Phase 3 programs from US, EU, and Japan-based sponsors across 7 mechanisms: Amyloid beta (3), Amyloid Beta-directed Antibody (1), PDE5 (1), Orexin 2R (1), M1/M4 muscarinic (1), APP/tau (1), 5-HT2A/NMDA (1). Novel classes not yet approved: PDE5, Amyloid beta, Orexin 2R, M1/M4 muscarinic, APP/tau, 5-HT2A/NMDA.
Disease-modifying
| Drug | Sponsor | Trial | Est. Readout |
|---|---|---|---|
| Lecanemab | Eisai | NCT03887455 | 2029-06 |
| AR1001 NEW | AriBio | NCT05531526 | 2026-05 |
| Donanemab | Eli Lilly | NCT05508789 | 2028-05 |
| Remternetug NEW | Eli Lilly | NCT06653153 | 2029-04 |
| Trontinemab NEW | Roche | NCT07170150 | 2028-06 |
| buntanetap/posiphen NEW | Annovis Bio | NCT06709014 | 2027-12 |
| Experimental: ALZ-801 NEW | Alzheon | NCT06304883 | 2026-12 |
Symptomatic
| Drug | Sponsor | Trial | Est. Readout |
|---|---|---|---|
| ACP-204 | ACADIA | NCT06159673 | 2028-01 |
| KarXT | Bristol-Myers Squibb | NCT05980949 | 2027-09 |
| EXV-802 | Exciva GmbH | NCT07284472 | 2029-01 |
Clinical Trial Analytics
Alzheimer's has the highest Phase 3 failure rate of any major disease. One in four late-stage trials ends in termination - three times the rate of diabetes or rheumatoid arthritis. Between 2014 and 2018, when BACE inhibitors dominated the pipeline, nearly half of all Phase 3 programs were killed. The human cost: 47,355 patients enrolled in Phase 3 trials that went nowhere.
Phase 3 Termination Rate vs Other Diseases
Source: ClinicalTrials.gov via TheraRadar trials-index.json (146,969 trials)
Notable Phase 3 Failures
9 major industry-sponsored programs that failed or were withdrawn in alzheimer's disease. Understanding what didn't work is as important as knowing what did.
| Drug | Sponsor | Trial | Year |
|---|---|---|---|
| Semaglutide EVOKE/EVOKE+: no slowing of cognitive decline vs placebo (March 2026) | Novo Nordisk | NCT04777396 | 2026 |
| Aducanumab (Aduhelm) Controversial approval (2021) overruling advisory panel; CMS restricted coverage; withdrawn Jan 2024 | Biogen | NCT02484547 | 2024 |
| Gantenerumab Failed to slow decline (GRADUATE I & II); insufficient amyloid clearance | Roche | NCT03444870 | 2022 |
| Aducanumab Ambiguous efficacy (EMERGE positive, ENGAGE negative); approved 2021, withdrawn 2024 | Biogen | NCT02484547 | 2022 |
| Semorinemab No effect on cognitive or functional decline | Roche | NCT03828747 | 2021 |
| Crenezumab Futility at interim analysis | Roche | NCT02670083 | 2019 |
| Elenbecestat Unfavorable risk-benefit, cognitive worsening | Biogen / Eisai | NCT02956486 | 2019 |
| Verubecestat No efficacy, cognitive worsening observed | Merck | NCT01953601 | 2018 |
| Solanezumab Failed to slow decline in mild AD | Eli Lilly | NCT02008357 | 2018 |
Stay Updated
Get notified when we publish new alzheimer's disease intelligence.
TheraRadar View
2026-04-21No new mechanism class was approved for Alzheimer's between 2003 (memantine) and 2021 - an 18-year drought. When aducanumab (Aduhelm) broke through in 2021 via accelerated approval, it became one of the most controversial FDA decisions in recent history: the clinical data was ambiguous, three advisory committee members resigned in protest, and Medicare initially limited coverage. Biogen withdrew it in 2024. But lecanemab (2023) and donanemab (2024) then proved the amyloid hypothesis with cleaner Phase 3 data - both slow cognitive decline by 25-35% in early-stage patients. The effect is real but modest, and comes with significant practical barriers: IV infusions, amyloid PET or CSF confirmation, MRI monitoring for ARIA (brain swelling/bleeding in 20-35% of patients).
The real question now isn't whether amyloid clearing works - it's whether it's enough. Anti-tau therapies have failed so far (semorinemab, zagotenemab). GLP-1 agonists were the most-watched alternative approach - but Novo Nordisk's EVOKE trials with oral semaglutide failed to slow cognitive decline in ~3,800 patients over two years, despite epidemiological signals suggesting dementia risk reduction in diabetes patients. The prevention hypothesis may still hold, but GLP-1 agonists are unlikely to become an Alzheimer's treatment. Blood-based biomarkers like p-tau217 remain the most promising near-term development - solving the access bottleneck by replacing amyloid PET scans with a simple blood test could do more to expand treatment than any new drug.